PHARMESIS INTERNATIONAL LTD. (BFK) fair value: what the stock is really worth
As of Nov 16, 2026: fair value (intrinsic value) of PHARMESIS INTERNATIONAL LTD. stock S$0.21, price S$0.08, upside +152.4%, quality 38 out of 100. Rating: strongly undervalued. Calculated from audited financials with 7 of our 26 valuation models and 37 quality factors, updated daily.
- Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free
PHARMESIS INTERNATIONAL LTD.
BFK · SGCheap (60% below fair value), but weak company and price moving sideways: meets 1 of 3 rules.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 14, 2026.
How to read this chart
60‑month range 0.0753 SGD – 0.6360 SGD · fair‑value band 0.1620 SGD – 0.2790 SGD · the 0.0820 SGD price screens below the 0.2070 SGD fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 14, 2026.
Every Wednesday you see whether PHARMESIS INTERNATIONAL is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Company profile
Pharmesis International Ltd., an investment holding company, research, develops, produces, packages, sells, and markets western medicines and traditional Chinese medicine (TCM) formulated products for hospitals and medical institutions in the People's Republic of China.
Show moreShow less
The company operates through three segments: Western drugs/TCH Procurement, TCM formulated drugs/IP Rental, and Distribution. It provides prescribed products and over-the-counter drugs.
The company offers Anethole Trithione for the treatment of illness relating to the liver and gall bladder; Xiao Shi Jian Pi to treat flatus, inappetency, dyspepsy, and spleen weakness; and Xiao Luo Tong for rheumatoid arthritis and other rheumatic diseases treatment.
It also provides Gansu for acute and chronic hepatitis treatment; Er Ding granules to treat jaundice and clear heat toxin; Shulinghou for the treatment of acute and chronic pharyngitis, laryngitis, sore throat, and hoarseness; Fu Yang for the treatment skin pruritus and urticaria; and Xiong Dan Chuan Bei for the treatment of phlegm and cough.
Further, the company distributes chemical drugs, biological raw products, TCM products, antibiotics, and antibiotic agents. The company provides western medicine products under the Kinna brand name; and TCM formulated products under the Longlife brand name.
Pharmesis International Ltd. was founded in 1996 and is based in Singapore.
Stock analysis
PHARMESIS INTERNATIONAL LTD. (BFK) currently trades at 0.0820 SGD, while our model-based Fair Value estimate is 0.2070 SGD, implying the stock looks roughly 60% undervalued today.
Show more
Valuation
Bull case: the Growth DCF group reads highest at a median of 0.2350 SGD per share, and 7 of the 7 models we run sit above the 0.0820 SGD price.
Bear case: the Multiples group reads lowest at 0.1200 SGD, and 0 of the 7 models stay below the price. Data coverage for this calculation is low.
Scenario range: 0.1620 SGD (bear) to 0.2790 SGD (bull), the price of 0.0820 SGD sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 38/100 (below-average quality), in the Healthcare sector.
Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.
PHARMESIS INTERNATIONAL LTD. reported revenue of 43.8M CNY in FY2025 versus 52.8M CNY in FY2021, a compound −4.6%/yr. Reported net income was −4.3M CNY in FY2025.
Key figures
Market cap 2.6M SGD (≈ $2.0M) Micro · P/S ratio 0.11 · EPS (TTM) −0.0400 SGD · Net margin −9.8% · Return on equity −13.1% · Return on assets (EBIT) −1.6% (5-year average) · Operating margin −34.3% · Revenue (TTM) 28.4M CNY.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 6 out of 100 (low confidence).
What moves the price
The share trades about 80% below its 52-week high and 6% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −27% fair-value upside, at 152%, BFK screens cheaper than that median.
Fair Value models
All 7 models by family
Quality Score breakdown
It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.
Revenue & earnings trend
Growth Forecast
Watch BFK, get fair value alerts →
Compare PHARMESIS INTERNATIONAL LTD. with another stock
Price, fair value, quality and upside side by side.
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 604 stocks
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
Strength profile in five axes (Snowflake)
Context: sector, industry, market
- Is the Health Care sector expensive or cheap?
- P/E, EV/EBITDA and margins by industry (reference tables)
- Net margin by industry
- P/B ratio by industry
- Piotroski F-Score screener with fair value
- Valuation of the Singapore market
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate.
| Stock | Price | Fair Value | vs Fair Value | Compare |
|---|---|---|---|---|
| Zoetis Inc ZTS | $84.39 | $113.53 | +35% | vs BFK |
| Jiangsu Hengrui Pharmaceuticals Co 600276 | ¥48.02 | ¥53.04 | +10% | vs BFK |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,868 | ₹1,983 | +6% | vs BFK |
| Haleon plc HLN | $9.20 | $8.47 | −8% | vs BFK |
| Merck KGaA MRK | €149.70 | €108.83 | −27% | vs BFK |
| Galderma Group GALD | CHF 191.00 | CHF 112.46 | −41% | vs BFK |
| Takeda Pharmaceutical Company TAK | $21.59 | $11.23 | −48% | vs BFK |
| Teva Pharmaceutical Industries Limited TEVA | $42.57 | $20.74 | −51% | vs BFK |
| Sandoz Group SDZ | CHF 84.60 | CHF 40.54 | −52% | vs BFK |
| Divi's Laboratories Limited DIVISLAB | ₹11,080 | ₹1,567 | −86% | vs BFK |
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is PHARMESIS INTERNATIONAL LTD. (BFK) overvalued or undervalued?
What is the fair value of BFK?
What is the quality score of BFK?
What is the price target for PHARMESIS INTERNATIONAL LTD. (BFK)?
What is the PHARMESIS INTERNATIONAL LTD. stock forecast for 2026?
What is the revenue of PHARMESIS INTERNATIONAL LTD. (BFK)?
What growth is priced into PHARMESIS INTERNATIONAL LTD. (BFK)?
What discount rate (WACC) does the fair value of BFK use?
What is a reverse DCF?
How much growth has PHARMESIS INTERNATIONAL LTD. (BFK) delivered so far?
How fast is the sector of PHARMESIS INTERNATIONAL LTD. (BFK) growing?
What is the free cash flow yield of PHARMESIS INTERNATIONAL LTD. (BFK)?
What is the intrinsic value of PHARMESIS INTERNATIONAL LTD. (BFK)?
Is PHARMESIS INTERNATIONAL LTD. stock overvalued or undervalued in 2026?
Is fair value the same as the market price of BFK?
How much is PHARMESIS INTERNATIONAL LTD. worth?
What do the bullish and bearish scenarios say about BFK?
How solid is the balance sheet of PHARMESIS INTERNATIONAL LTD. (BFK)?
How far is BFK from its 52-week high?
Which stocks are comparable to PHARMESIS INTERNATIONAL LTD.?
Is PHARMESIS INTERNATIONAL LTD. stock attractive at the current price?
How is the fair value of BFK calculated?
Is it still worth investing in stocks now?
What is the share price of PHARMESIS INTERNATIONAL LTD. (BFK)?
What should I pay attention to with PHARMESIS INTERNATIONAL LTD. right now?
Key figures of PHARMESIS INTERNATIONAL LTD.
How large is the market capitalisation of PHARMESIS INTERNATIONAL LTD. (BFK)?
What is the P/S ratio of PHARMESIS INTERNATIONAL LTD. (BFK)?
What are the earnings per share of PHARMESIS INTERNATIONAL LTD. (BFK)?
What is the net margin of PHARMESIS INTERNATIONAL LTD. (BFK)?
What is the return on equity of PHARMESIS INTERNATIONAL LTD. (BFK)?
What is the EBIT return on assets of PHARMESIS INTERNATIONAL LTD. (BFK)?
What is the operating margin of PHARMESIS INTERNATIONAL LTD. (BFK)?
How fast is revenue growing at PHARMESIS INTERNATIONAL LTD. (BFK)?
How much net debt does PHARMESIS INTERNATIONAL LTD. (BFK) carry?
Watch PHARMESIS INTERNATIONAL LTD. in the live analysis
One click puts PHARMESIS INTERNATIONAL LTD. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.